What's wrong with the FDA? Are safety concerns emphasized at the expense of needed therapies? Are drugs approved too quickly or not fast enough? And whatever your view, who's to blame? A recent segment on CNBC's Squawkbox tries to sort it out with help from Joel Sendek, a Lazard Capital Markets managing director and biotech analyst, and Paul Brown, a consumer healthcare advociate with the Public Interest Research Group.
Click on this link to
watch the video.
Jawboning About Drug Safety And Approvals
What's wrong with the FDA? Are safety concerns emphasized at the expense of needed therapies? Are drugs approved too quickly or not fast enough? And whatever your view, who's to blame? A recent segment on CNBC's Squawkbox tries to sort it out with help from Joel Sendek, a Lazard Capital Markets managing director and biotech analyst, and Paul Brown, a consumer healthcare advociate with the Public Interest Research Group.
Click on this link to
watch the video.